Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults

Overview

Journal J Am Geriatr Soc

Specialty Geriatrics

Date 2017 Aug 24

PMID 28832920

Citations 12

Authors

Raymond B Fohtung

Eric Novak

Michael W Rich

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the effect of new oral anticoagulants (NOACs) on prescribing practices in older adults with atrial fibrillation (AF).

Design: Retrospective observational cohort study.

Setting: Academic medical center in St. Louis, Missouri.

Participants: Individuals aged 75 and older with AF admitted to the hospital from October 2010 through September 2015 (N = 6,568, 50% female, 15% non-white).

Measurements: Information on NOACs and warfarin prescribed at discharge was obtained from hospital discharge summaries, and linear regression was used to examine quarterly trends in their use. Multivariable logistic regression was used to assess independent predictors of anticoagulant use.

Results: NOAC use increased over time (correlation coefficient (r) = 0.87, P < .001), warfarin use did not change (r = -0.16, P = .50), and overall anticoagulant use (NOACs and warfarin) increased (r = 0.68, P = .001). NOAC use increased over time in all age groups (75-79, 80-84, 85-89) except aged 90 and older, but increasing age attenuated the rate of NOAC uptake. There was no consistent relationship between age and warfarin or overall anticoagulant use, except that individuals aged 90 and older had consistently lower use. Overall, fewer than 45% of participants were prescribed an anticoagulant. In multivariable analysis, younger age, white race, female sex, higher hemoglobin, higher creatinine clearance, being on a medical service, hypertension, stroke or transient ischemic attack, no history of intracranial hemorrhage, and a modified HAS-BLED score of less than 3 increased the likelihood of receiving NOACs.

Conclusion: Prescription of anticoagulants for AF increased in older adults primarily because of an increase in the use of NOACs. Nonetheless, fewer than 45% of participants were prescribed an anticoagulant. Additional research is needed to optimize prescribing practices for older adults with AF.

Citing Articles

Differences in quality of anticoagulation care delivery according to ethnoracial group in the United States: A scoping review.

Vazquez S, Yates N, Beavers C, Triller D, McFarland M J Thromb Thrombolysis. 2024; 57(6):1076-1091.

PMID: 38733515 PMC: 11315726. DOI: 10.1007/s11239-024-02991-2.

Drug-Drug Interactions with Oral Anticoagulants as Potentially Inappropriate Medications: Prevalence and Outcomes in Elderly Patients in Primary Care and Hospital Settings.

Bories M, Bouzille G, Cuggia M, Le Corre P Pharmaceutics. 2022; 14(7).

PMID: 35890305 PMC: 9325322. DOI: 10.3390/pharmaceutics14071410.

Synthesis of the evidence on the impact of pre-operative direct oral anticoagulants on patient health outcomes after hip fracture surgery: rapid systematic review.

Mitchell R, Jakobs S, Halim N, Seymour H, Tarrant S Eur J Trauma Emerg Surg. 2022; 48(4):2567-2587.

PMID: 35275244 PMC: 9360144. DOI: 10.1007/s00068-022-01937-8.

Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Bonanad C, Garcia-Blas S, Torres Llergo J, Fernandez-Olmo R, Diez-Villanueva P, Ariza-Sole A J Clin Med. 2021; 10(22).

PMID: 34830548 PMC: 8618042. DOI: 10.3390/jcm10225268.

Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study.

Mitchell A, Snowball J, Welsh T, Watson M, McGrogan A BMC Med. 2021; 19(1):189.

PMID: 34461899 PMC: 8406735. DOI: 10.1186/s12916-021-02067-5.

References

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21):e1-76. DOI: 10.1016/j.jacc.2014.03.022. View

Landefeld C, Beyth R . Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993; 95(3):315-28. DOI: 10.1016/0002-9343(93)90285-w. View

Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J . Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015; 63(1):71-6. DOI: 10.1111/jgs.13200. View

Camm A, Accetta G, Ambrosio G, Atar D, Bassand J, Berge E . Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2016; 103(4):307-314. PMC: 5293840. DOI: 10.1136/heartjnl-2016-309832. View

Weitz J, Semchuk W, Turpie A, Fisher W, Kong C, Ciaccia A . Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther. 2015; 37(11):2506-2514.e4. DOI: 10.1016/j.clinthera.2015.09.008. View

Gage B, Boechler M, Doggette A, Fortune G, Flaker G, Rich M . Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2001; 31(4):822-7. DOI: 10.1161/01.str.31.4.822. View

Shafeeq H, Tran T . New oral anticoagulants for atrial fibrillation: are they worth the risk?. P T. 2014; 39(1):54-64. PMC: 3956385. View

Gage B, Waterman A, Shannon W, Boechler M, Rich M, Radford M . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-70. DOI: 10.1001/jama.285.22.2864. View

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

10.

Barnes G, Lucas E, Alexander G, Goldberger Z . National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015; 128(12):1300-5.e2. PMC: 4658248. DOI: 10.1016/j.amjmed.2015.05.044. View

11.

Desai N, Krumme A, Schneeweiss S, Shrank W, Brill G, Pezalla E . Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014; 127(11):1075-1082.e1. DOI: 10.1016/j.amjmed.2014.05.013. View

12.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

13.

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

14.

Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013; 383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0. View

15.

Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U . Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2014; 40(1):97-107. DOI: 10.1007/s11239-014-1136-8. View

16.

Stangier J . Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47(5):285-95. DOI: 10.2165/00003088-200847050-00001. View

17.

Patel P, Zhao X, Fonarow G, Lytle B, Smith E, Xian Y . Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes. 2015; 8(4):383-92. PMC: 4512906. DOI: 10.1161/CIRCOUTCOMES.114.000907. View

18.

Orkaby A, Ozonoff A, Reisman J, Miller D, Zhao S, Rose A . Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. J Am Geriatr Soc. 2017; 65(2):249-256. DOI: 10.1111/jgs.14573. View

19.

Brass L, Krumholz H, Scinto J, Mathur D, Radford M . Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998; 158(19):2093-100. DOI: 10.1001/archinte.158.19.2093. View

20.

Kirley K, Qato D, Kornfield R, Stafford R, Alexander G . National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012; 5(5):615-21. PMC: 3490619. DOI: 10.1161/CIRCOUTCOMES.112.967299. View